Transdermal Pain Management to 2020- Products, Markets, Opportunities and Forecasts
|発行||Greystone Research Associates||商品コード||138804|
|経皮的疼痛管理：製品・市場・予測・機会 Transdermal Pain Management to 2020- Products, Markets, Opportunities and Forecasts|
|出版日: 2014年12月01日||ページ情報: 英文||
‘Transdermal Pain Management to 2020: Products, Markets, Opportunities and Forecasts’ is a comprehensive evaluation and analysis of the technology, products and participants providing the driving force behind this evolving segment of the pain management drug sector.
The study is designed to provide drug company decision makers, pain product managers, drug delivery developers, device designers, healthcare marketers, and supply chain participants with a detailed understanding of the economics, technologies, treatable conditions, and commercial opportunities for transdermal pain management. Provider organization business managers, healthcare administrators and investors will also benefit from this study.
As life expectancy in the developed world increases and populations age, the incidence and associated morbidity of chronic and acute pain is increasing and placing a higher level of emphasis on pain management as a quality-of-life issue for patients and their families. Responding to this trend, drug developers are increasingly turning to transdermal formulations of pain management drugs. Because it has the potential to improve drug therapy compliance, transdermal delivery addresses a key healthcare issue - one that is particularly problematic in aging populations and developing economies. Currently approved transdermal pain products include narcotics, NSAIDs, and topical anesthetics. These patches and gels will encounter competition from development-stage transdermal formulations for a number of pain medications presently being marketed in oral or parenteral form. Several of these development programs involve international partnerships designed to take advantage of perceived opportunities in regional markets.